Scarica l'app Stockscreener
2.75
1.10%
0.03
Dopo l'orario di chiusura:
2.77
0.02
+0.73%
Precedente Chiudi:
$2.72
Aprire:
$2.72
Volume 24 ore:
802.71K
Relative Volume:
1.80
Capitalizzazione di mercato:
$289.33M
Reddito:
$7.05M
Utile/perdita netta:
$-30.43M
Rapporto P/E:
-7.2598
EPS:
-0.3788
Flusso di cassa netto:
$21.84M
1 W Prestazione:
-5.50%
1M Prestazione:
+29.11%
6M Prestazione:
+65.66%
1 anno Prestazione:
-21.43%
Intervallo 1D:
$2.645
$2.76
Intervallo di 1 settimana:
$2.60
$3.00
Portata 52W:
$1.07
$4.21
Proqr Therapeutics N V Stock (PRQR) Company Profile
Nome
Proqr Therapeutics N V
Settore
Industria
Telefono
-
Indirizzo
-
Confronta PRQR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
2.75 | 286.54M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-29 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-04-29 | Iniziato | Evercore ISI | Outperform |
| 2025-03-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-01-10 | Iniziato | Oppenheimer | Outperform |
| 2024-10-29 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2022-02-11 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | Downgrade | Stifel | Buy → Hold |
| 2022-02-01 | Iniziato | Raymond James | Strong Buy |
| 2021-05-03 | Iniziato | Stifel | Buy |
| 2021-03-25 | Reiterato | Citigroup | Buy |
| 2020-11-03 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-03-12 | Reiterato | Chardan Capital Markets | Buy |
| 2018-12-19 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-11-15 | Iniziato | Citigroup | Buy |
| 2018-09-19 | Iniziato | Evercore ISI | Outperform |
| 2017-09-26 | Reiterato | JMP Securities | Mkt Outperform |
| 2016-06-20 | Iniziato | Chardan Capital Markets | Neutral |
| 2014-10-15 | Iniziato | Deutsche Bank | Buy |
| 2014-10-13 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Proqr Therapeutics N V Borsa (PRQR) Ultime notizie
Will ProQR Therapeutics N.V. stock gain from government policies2025 Investor Takeaways & Long-Term Safe Investment Plans - newser.com
Is ProQR Therapeutics N.V. stock a good choice for value investorsPortfolio Update Report & Reliable Price Breakout Alerts - newser.com
How sentiment analysis helps forecast ProQR Therapeutics N.V.2025 Top Gainers & AI Enhanced Trading Alerts - newser.com
What catalysts could drive ProQR Therapeutics N.V. stock higherDay Trade & Weekly Top Stock Performers List - newser.com
ProQR Therapeutics N.V. (NASDAQ:PRQR) Short Interest Update - MarketBeat
Custom watchlist performance reports with ProQR Therapeutics N.V.Bear Alert & Verified Trade Idea Suggestions - newser.com
What’s the recovery path for long term holders of ProQR Therapeutics N.V.July 2025 Snapshot & Daily Profit Focused Screening - newser.com
Is ProQR Therapeutics N.V. stock attractive for growth ETFsJuly 2025 Technicals & Community Supported Trade Ideas - newser.com
ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Visualizing ProQR Therapeutics N.V. stock with heatmapsTrade Entry Summary & Long Hold Capital Preservation Tips - newser.com
Is ProQR Therapeutics N.V. stock cheap at current valuationJuly 2025 PostEarnings & Precise Buy Zone Identification - newser.com
ProQR Therapeutics NV expected to post a loss of 10 cents a shareEarnings Preview - TradingView
ProQR Therapeutics (PRQR) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Why analysts recommend ProQR Therapeutics N.V. (0PQ) stockMarket Volume Report & Entry Point Confirmation Signals - newser.com
Does ProQR Therapeutics N.V. stock trade at a discount to peersBreakout Watch & Low Risk High Win Rate Picks - newser.com
Key metrics from ProQR Therapeutics N.V.’s quarterly dataWeekly Risk Report & AI Powered Market Entry Strategies - newser.com
Is ProQR Therapeutics N.V. (0PQ) stock at risk of policy regulation2025 Top Gainers & AI Enhanced Trading Alerts - newser.com
Will ProQR Therapeutics N.V. stock outperform international peersQuarterly Portfolio Summary & Technical Confirmation Trade Alerts - newser.com
ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Above 50-Day Moving AverageTime to Sell? - MarketBeat
Is ProQR Therapeutics N.V. stock a safe buy before earnings2025 Technical Patterns & AI Forecast for Swing Trade Picks - fcp.pa.gov.br
Proqr Therapeutics N V Azioni (PRQR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.62%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):